Samsung BioLogics

Samsung Biologics is a fully integrated, end-to-end CDMO service provider offering seamless development and manufacturing solutions from cell line development to final aseptic fill/finish as well as laboratory testing services at every stage for biopharmaceutical products. To maximize our operational efficiency and expand our capabilities in response to growing biomanufacturing demands, Samsung Biologics launched Plant 4, which will further advance the company’s standing as the world’s largest manufacturing facility at a single site—holding a 604KL total capacity—and announced plans to construct Plant 5, which will be operational in 2025. As a sustainable CDMO partner of choice, we are committed to on-time, in-full delivery of the products we manufacture with our flexible manufacturing solutions, operational excellence, and proven expertise. What strategies are being employed to accelerate product development and commercialization without compromising quality? How can pharmaceutical and biopharmaceutical companies demonstrate their commitment to ESG principles in manufacturing? Accelerating the development and production of high quality bispecific antibodies.